2.03%
7.09%
-2.79%
-11.52%
12.41%
-25.15%
-32.08%
AI Spotlight on CEVI
Company Description
CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific.The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer.It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process.
In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology.It sells its products to hospital and commercial laboratories.CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.
Market Data
| Last Price | 226.5 |
| Change Percentage | 2.03% |
| Open | 222.5 |
| Previous Close | 222 |
| Market Cap ( Millions) | 5402 |
| Volume | 16027 |
| Year High | 302 |
| Year Low | 197.2 |
| M A 50 | 217.14 |
| M A 200 | 247.19 |
Financial Ratios
| FCF Yield | 2.82% |
| Dividend Yield | 0.99% |
| ROE | 20.15% |
| Debt / Equity | 4.61% |
| Net Debt / EBIDTA | -44.54% |
| Price To Book | 7.04 |
| Price Earnings Ratio | 35.96 |
| Price To FCF | 35.44 |
| Price To sales | 7.33 |
| EV / EBITDA | 23.08 |
News
- Jan -10 - Uncovering 3 Stocks Considered Undervalued Based On Current Estimates
- Dec -12 - 3 Stocks Estimated To Be Up To 47.4% Below Intrinsic Value
- Oct -25 - CellaVision AB (CLVSF) Q3 2024 Earnings Call Highlights: Strong Organic Growth Amid Market ...
- Oct -25 - 3 Swedish Stocks Estimated To Be Trading At Discounts Of Up To 40.9%
- Sep -20 - 3 Swedish Stocks Estimated To Be Undervalued In September 2024
- Sep -05 - CellaVision And 2 Other Swedish Stocks Estimated To Be Trading Below Fair Value
- Aug -06 - CellaVision And 2 Swedish Stocks Estimated To Be Trading Below Intrinsic Value
- Jul -22 - Exploring Value Opportunities on the Swedish Exchange in July 2024
- Jul -05 - Swedish Exchange Stocks Estimated Below Intrinsic Values in July 2024
- Jun -20 - June 2024 Insights Into Three Swedish Stocks Estimated Below Value
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Instruments
Expected Growth : 12 %
What the company do ?
CellaVision AB (publ) offers digital morphology instruments for labs, enabling automated blood cell differential counts, cell imaging, and manual review.
Why we expect these perspectives ?
CellaVision AB's 12% growth is driven by increasing adoption of digital pathology solutions, expansion into new markets, and growing demand for automated blood cell analysis. Strong sales of its flagship product, DM1200, and increasing recurring revenue from software and services also contribute to the growth. Additionally, strategic partnerships and investments in R&D further support the company's expansion.
Segment n°2 -> Software and Other
Expected Growth : 14 %
What the company do ?
CellaVision AB (publ) provides software and digital morphology solutions for medical labs, enabling efficient and accurate blood cell differential counts and cell morphology analysis.
Why we expect these perspectives ?
CellaVision AB's 14% growth in Software and Other is driven by increasing demand for digital pathology solutions, expansion into new markets, and growing adoption of artificial intelligence in healthcare. Additionally, the company's strategic partnerships and investments in research and development have contributed to the growth.
Segment n°3 -> Reagents
Expected Growth : 11 %
What the company do ?
Reagents from CellaVision AB (publ) are high-quality diagnostic solutions for digital microscopy, enabling accurate and efficient blood cell differential counts and morphology analysis.
Why we expect these perspectives ?
CellaVision AB's 11% growth in Reagents is driven by increasing adoption of digital morphology in hematology, rising demand for automated blood cell analysis, and expansion into new geographies. Additionally, the company's focus on product innovation, strategic partnerships, and growing customer base contribute to its growth momentum.
Cellavision Ab (Publ) Products
| Product Range | What is it ? |
|---|---|
| CellaVision DM96 | A digital microscope system for remote blood cell morphology analysis |
| CellaVision DC-1 | A digital cell morphology system for automated blood cell differential counting |
| CellaVision DM1200 | A digital microscope system for remote blood cell morphology analysis with advanced image analysis |
| CellaVision Remote Review | A software solution for remote review and validation of blood cell morphology |
| CellaVision Image Analysis | A software solution for advanced image analysis of blood cells |
CellaVision AB (publ)'s Porter Forces
Threat Of Substitutes
The threat of substitutes for CellaVision AB (publ) is moderate due to the presence of alternative solutions in the market, but the company's strong brand recognition and customer loyalty mitigate this threat.
Bargaining Power Of Customers
The bargaining power of customers is low for CellaVision AB (publ) as the company operates in a niche market with limited competition, giving customers limited alternatives.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate for CellaVision AB (publ) as the company relies on a few key suppliers for critical components, but has some flexibility to negotiate prices.
Threat Of New Entrants
The threat of new entrants is low for CellaVision AB (publ) due to the high barriers to entry in the medical technology industry, including significant research and development costs and regulatory hurdles.
Intensity Of Rivalry
The intensity of rivalry is high for CellaVision AB (publ) as the company operates in a competitive market with several established players, leading to aggressive marketing and pricing strategies.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 8.28% |
| Debt Cost | 6.35% |
| Equity Weight | 91.72% |
| Equity Cost | 9.36% |
| WACC | 9.11% |
| Leverage | 9.03% |
CellaVision AB (publ) : Quality Control
CellaVision AB (publ) passed 9 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| INMD | InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and … |
| CHEMM.CO | ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in … |
| EUZ.DE | Eckert & Ziegler Strahlen- und Medizintechnik AG, through its subsidiaries, manufactures and sells isotope technology components for medical, scientific, and industrial applications worldwide. It operates in two segments, Medical and … |
| GBT.PA | Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and … |
| XVIVO.ST | Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
ChemoMetec
A-Score
1-Year Total Return ->
🥈
InMode
A-Score
1-Year Total Return ->
🥉
Guerbet
A-Score
1-Year Total Return ->
4
CellaVision
A-Score
1-Year Total Return ->
5
Eckert & Ziegler
A-Score
1-Year Total Return ->
6
